Monday, 18 Jun 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
04 Apr 2017 Social FDAs Oncology Advisory Committee votes 11-0 approve subcut rituximab for lymphoma & CLL. Given in minutes not hours
13 Mar 2017 Social Review of severe alopecia areata 90pts Rx w/ Xeljanz: 20% nearly total regrowth, 58% >50% regrowth,77% some regrowth
09 Mar 2017 News European Biologic Manufacturers Issue Warnings About Biosimilar Switching
07 Mar 2017 Social Placebo outperforms Anakinra (22% vs 8%) in 50 patients with chronic Fatigue Syndrome. IL-1 inhibition fails in CFS
28 Feb 2017 Social Just like Oral Strategy Study (MTX+Tofa > Tofa), DREAM registry shows TNFi + MTX > TNFi.
27 Feb 2017 News High Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab
23 Feb 2017 News Sirukumab Effective in Rheumatoid Arthritis
20 Feb 2017 News Abatacept Efficacy Giant Cell Arteritis
20 Feb 2017 Social Dr Mahadevan #RWCS17 ustekinumab has been approved for Crohns disease
17 Feb 2017 Social RT @DrRachelTate: No changes in safety, efficacy, or ab production in IFX vs inflectra. Eric Ruderman, MD & Arthur Kavanaugh, MD #rwcs2017…
17 Feb 2017 News Biosimilar Reports – February 2017
17 Feb 2017 Social Dr Kevin Winthrop at #RWCS2017 reviews DMARD/Biologic effects on vaccine responses. Most effected by RTX, least by…
17 Feb 2017 Social ORAL strategy trial shows Xeljanz +MTX = Humira +MTX; but was inferior as monoRx Xeljanz in 1152 RA pts over 12 mos
17 Feb 2017 Social RT @DrRachelTate: JAK profiles in vitro as described by Mark Genovese, MD @RheumNow @RWCSmtg
16 Feb 2017 News BEAM Study: Baricitinib Beats Placebo and Adalimumab in Rheumatoid Arthritis
16 Feb 2017 Social 100% of RA pts having all 3 factors(seropositivity; high IgG levels;detectable serum IL-33) will respond to Rituxan
15 Feb 2017 Social RT @DrRachelTate: JAK profiles in vitro as described by Mark Genovese, MD @RheumNow @RWCSmtg
15 Feb 2017 Social Correction: Abbvies JAK inhibitor ABT-494) has a name, Uptacitinib, is currently in phIII trials. #RWCS 2017 info from Dr. M Genovese
15 Feb 2017 News Baricitinib Approved in the EU for Use in Rheumatoid Arthritis
15 Feb 2017 Social Baricitinib (AKA Olumiant ) approved by EMA for use in EU for moderate-to-severe RA as monotherapy or combo w/ MTX